Ormond's disease - the current state of knowledge about diagnosis and treatment
DOI:
https://doi.org/10.12775/JEHS.2022.12.09.071Keywords
retroperitoneal fibrosis, Ormond's disease, glucocorticosteroid therapy, immunosuppressive treatment, IgG4-related diseaseAbstract
Introduction: Retroperitoneal fibrosis (Ormond's disease; RPF) is a rare condition characterized by chronic inflammation and resulting progressive fibrosis of the retroperitoneal space. Due to its low prevalence and uncharacteristic symptoms, it is often overlooked in the diagnostic process, resulting in a late-stage diagnosis when complications are already present and treatment options are limited.
The aim of the study: The purpose of our study was to present, based on the available literature, the latest reports on the diagnosis and treatment of Ormond disease.
State of knowledge: The diagnosis of RPF is based on an anamnesis and imaging. Sometimes a surgical biopsy of the fibrous tissue is necessary. The pathogenesis remains partly unclear. There is no characteristic laboratory marker for early diagnosis of the disease. It is important to distinguish the primary form from the secondary form, in which the trigger factors are known. In therapy, steroid therapy is still the standard. Attempts are being made to treat with other immunosuppressants and biologic drugs with good results, which speaks to the autoimmune basis of the disease. In some cases, surgical treatment and removal of fibrous tissue compressing abdominal structures is essential.
Summary: Although the state of knowledge about retroperitoneal fibrosis has been greatly expanded in recent years, many questions remain to be clarified, especially about its pathogenesis and possible early clinical clues to facilitate diagnosis.
References
Engelsgjerd JS, LaGrange CA. Retroperitoneal Fibrosis. 2021 Sep 14. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 29494016.
Łoń I, Wieliczko M, Lewandowski J, et al. Retroperitoneal Fibrosis Is Still an Underdiagnosed Entity with Poor Prognosis. Kidney Blood Press Res. 2022;47(3):151-162. doi: 10.1159/000521423. Epub 2021 Dec 10. PMID: 34915518.
Runowska M, Majewski D, Puszczewicz M. Retroperitoneal fibrosis - the state-of-the-art. Reumatologia. 2016;54(5):256-263. doi: 10.5114/reum.2016.63667. Epub 2016 Nov 28. PMID: 27994271; PMCID: PMC5149574. (TO TEN POLSKI 1.)
Angarola E, Valeo Chulvi M, Peuchot V, et al. Immunoglobulin G4-related retroperitoneal fibrosis. Medicina (B Aires). 2022;82(1):91-98. English. PMID: 35037866.
Miller OF, Smith LJ, Ferrara EX, et al. Presentation of idiopathic retroperitoneal fibrosis in the pediatric population. J Pediatr Surg. 2003 Nov;38(11):1685-8. doi: 10.1016/s0022-3468(03)00590-6. PMID: 14614727.
van Bommel EFH, Jansen I, Hendriksz TR, et al. Idiopathic retroperitoneal fibrosis: prospective evaluation of incidence and clinicoradiologic presentation. Medicine (Baltimore). 2009 Jul;88(4):193-201. doi: 10.1097/MD.0b013e3181afc420. PMID: 19593223.
Gormley S, Bravo PT, Kos X, et al. A case of IgG4-related retroperitoneal fibrosis with significant involvement of the abdominal aorta-a clinical and diagnostic challenge. J Vasc Surg Cases Innov Tech. 2022 Mar 8;8(2):275-280. doi: 10.1016/j.jvscit.2022.02.003. PMID: 35586678; PMCID: PMC9108322.
Pfitzenmeyer P, Foucher P, Dennewald G, et al. Pleuropulmonary changes induced by ergoline drugs. Eur Respir J. 1996 May;9(5):1013-9. doi: 10.1183/09031936.96.09051013. PMID: 8793465.
Alberti C. Drug-induced retroperitoneal fibrosis: short aetiopathogenetic note, from the past times of ergot-derivatives large use to currently applied bio-pharmacology. G Chir. 2015 Jul-Aug;36(4):187-91. doi: 10.11138/gchir/2015.36.4.187. PMID: 26712075; PMCID: PMC4732590.
Couderc M, Mathieu S, Dubost JJ, et al. Retroperitoneal fibrosis during etanercept therapy for rheumatoid arthritis. J Rheumatol. 2013 Nov;40(11):1931-3. doi: 10.3899/jrheum.130324. PMID: 24187163.
Brandt AS, Kamper L, Kukuk S, et al. Associated findings and complications of retroperitoneal fibrosis in 204 patients: results of a urological registry. J Urol. 2011 Feb;185(2):526-31. doi: 10.1016/j.juro.2010.09.105. Epub 2010 Dec 18. PMID: 21168884.
Gao L, Wang H, Xu Y, et al. Computed tomography parameters can be used as predictive markers for the improvement of renal function in patients with retroperitoneal fibrosis. Clin Exp Rheumatol. 2015 Nov-Dec;33(6):871-6. Epub 2015 Oct 30. PMID: 26516692.
Cristian S, Cristian M, Cristian P, et al. Management of idiopathic retroperitoneal fibrosis from the urologist's perspective. Ther Adv Urol. 2015 Apr;7(2):85-99. doi: 10.1177/1756287214565637. Erratum in: Ther Adv Urol. 2016 Apr;8(2):161-2. PMID: 25829952; PMCID: PMC4372523.
Warnatz K, Keskin AG, Uhl M, et al. Immunosuppressive treatment of chronic periaortitis: a retrospective study of 20 patients with chronic periaortitis and a review of the literature. Ann Rheum Dis. 2005 Jun;64(6):828-33. doi: 10.1136/ard.2004.029793. PMID: 15897305; PMCID: PMC1755530.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Sara Dankiewicz, Sebastian Bróż, Przemysław Żelazny, Joanna Filipczak, Aleksandra Swora, Joanna Borowik, Oliwer Sygacz, Wojciech Brodowski, Piotr Pawłowski, Katarzyna Basta-Arciszewska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 584
Number of citations: 0